EICHORPublic-registry site landscape for NCT07702890, “A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D”, a Obesity study sponsored by Gubra A/S. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07702890 (registry record) |
| Study title | A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D |
| Official title | A Three-part First-in-human, Single and Multiple Ascending and Repeated Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous GUB-UCN2 in Healthy Lean and Obese Participants and in Participants With Type 2 Diabetes |
| Sponsor | Gubra A/S |
| Condition(s) | Obesity; Type 2 Diabetes |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 0 |
Patient-friendly overview of this study: eichor.com/study/NCT07702890.
Eichor generates a preliminary site-risk snapshot for NCT07702890 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Obesity trials
← Eichor home · All tracked trials · Obesity studies · Weekly briefs
